[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[2] 张福奎,贾继东,王宝恩. 慢性乙型肝炎的治疗. 中华肝脏病杂志,2000,8 （4）:253.
[3] Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B:A review. Hepatology,2011,54（2）:E1-9.
[4] Brunetto MR,Moriconi F,Bonino F,et al. Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology,2008,49:1141-1150.
[5] Sung JJ,Tsoi KK,Li KC,et al. Meta-analysis：treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther,2008,28：1067-1077.
[6] Chan HL,Wong VW,Wong GL,et al. Early hepatitis B virus DNA suppression can predict virological response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol,2008,6：1022-1026.
[7] Wong GL,Chan HL. Predictors of treatment response in chronic hepatitis B. Drug,2009,69：2167-2177.
[8] Buster EH,Hansen BE,Lau GK,et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology,2009,137: 2002-2009.
[9] Ter Borg MJ,Van Zonneveld M,Zeuzem S,et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B:relation to treatment response. Hepatology,2006,44：721-727.
[10] European Association for the Study of the Liver. EASL clinical practice guidelines：management of chronic hepatitis B. J Hepatol,2009,50: 227-242.
[11] Arai M,Togo S,Kanda T,et al. Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance. Eur J Gastroenterol Hepatol, 2012,[Epub ahead of print].
（校对：陈宗炳） |
